Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

INTRODUCTION: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) improve hepatic dysfunction, although studies focusing on their underlying mechanisms are lacking, especially ones on dapagliflozin and empagliflozin. Here, we investigated the relationship between amelioration of hepatic dysfunction...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Lee, Paul Chi Ho, Gu, Yunjuan, Yeung, Man Yi, Fong, Carol Ho Yi, Woo, Yu Cho, Chow, Wing Sun, Tan, Kathryn, Lam, Karen Siu Ling
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801241/
https://ncbi.nlm.nih.gov/pubmed/29322486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0355-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars